Modeling the 4D study: Statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 5, 2010, Pages 856-866

  Chan, Kevin E ^a   Thadhani, Ravi ^b   Lazarus, J Michael ^a   Hakim, Raymond M ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN;

ACCURACY; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HEART DEATH; HEART INFARCTION; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MODEL; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; SIMULATION; STROKE; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; DATABASES AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77952296370     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07161009     Document Type: Article

References (49)

1. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342: 1887-1892, 2000
2. Preventive Services Task Force: Guide to Clinical Preventive Services: Report of the U.S. Preventive Service Task Force, 2nd Ed., Baltimore, Williams & Wilkins, 1996
3. Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N, Newman TB: Designing Clinical Research, 2nd Ed., Philadelphia, Lippincott Williams & Wilkins, 2001
4. Thadhani R, Tonelli M: Cohort studies: Marching forward. Clin J Am Soc Nephrol 1: 1117-1123, 2006
5. Ray WA: Observational studies of drugs and mortality. N Engl J Med 353: 2319-2321, 2005
6. US Renal Data System: USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008
7. Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chen K, Maroni BL, Wolfe RA, Held PJ. The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study. Kidney Int 57[Suppl 74]: S74-S81, 2000
8. Greene T: Randomized and observational studies in nephrology: How strong is the evidence? Am J Kidney Dis 53: 377-388, 2009
9. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005 (Pubitemid 41058323)
10. Wanner C, Krane V, Ruf G, Marz W, Ritz E: Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl 71: S222-S226, 1999
11. Chan KE, Lazarus JM, Thadhani R, Hakim RM: Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 20: 872-881, 2009
12. Chan KE, Lazarus JM, Wingard RL, Hakim RM: Association between repeat hospitalization and early intervention in dialysis patients following hospital discharge. Kidney Int 76: 331-341, 2009
13. Chan KE, Lazarus JM, Thadhani R, Hakim RM: Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20: 2223-2233, 2009
14. Lacson E Jr, Wang W, Hakim RM, Teng M, Lazarus JM: Associates of mortality and hospitalization in hemodialysis: Potentially actionable laboratory variables and vascular access. Am J Kidney Dis 53: 79-90, 2009
15. Lowrie EG, Teng M, Lacson E, Lew N, Lazarus JM, Owen WF: Association between prevalent care process measures and facility-specific mortality rates. Kidney Int 60: 1917-1929, 2001
16. Broome CV, Loonsk J: Public Health Information Network: Improving early detection by using a standards-based approach to connecting public health and clinical medicine. MMWR Morb Mortal Wkly Rep 53[Suppl]: 199-202, 2004
17. Centers for Disease Control and Prevention: Updated guidelines for evaluating public health surveillance systems: Recommendations from the guidelines working group. MMWR Recomm Rep 50: 1-35, 2001
18. Wanner C. Lipid lowering and cardiovascular outcomes in type-two diabetics on dialysis: The 4D trial. Presented at the annual meeting of the American Society of Nephrology; October 27-November 1, 2004; St. Louis, MO
19. Kosanke J, Bergstralh E: Gmatch: SAS macro. Available at: http://mayoresearch.mayo.edu/mayo/research/biostat/upload/gmatch.sas. Accessed December 12, 2008
20. Rubin D: Matching to remove bias in observational studies. Biometrics 29: 159-183, 1973
21. Rosenbaum PR: Model-based direct adjustment. J Am Stat Assoc 82: 387-394, 1987
22. Hirano KI: Estimation of causal effects using propensity score weighting: An application to data on right heart catheterization. Health Serv Outcomes Res Methodol 2: 259-278, 2001
23. Rosenbaum P, Rubin D: The central role of the propensity score in observational studies for causal effect. Biometrika 70: 41-55, 1983
24. Jones P, Kafonek S, Laurora I, Hunninghake D: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81: 582-587, 1998 (Pubitemid 28182422)
25. Hunninghake D, Bakker-Arkema RG, Wigand JP, Drehobl M, Schrott H, Early JL, Abdallah P, McBride S, Black DM: Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract 47: 349-356, 1998 (Pubitemid 28541566)
26. Sasaki J, Arakawa K, Yamamoto K, Kobori S, Ageta M, Kono S: A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia. Clin Ther 20: 539-548, 1998 (Pubitemid 28343506)
27. Imbens G: The role of propensity score in estimating doseresponse in observational studies for causal effect. Biometrika 3: 706-710, 2000
28. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001
29. Chertow GM, Johansen KL, Lew N, Lazarus JM, Lowrie EG: Vintage, nutritional status, and survival in hemodialysis patients. Kidney Int 57: 1176-1181, 2000 (Pubitemid 30434807)
30. Byar DP, Simon RM, Friedewald WT, Schlesselman JJ, DeMets DL, Ellenberg JH, Gail MH, Ware JH: Randomized clinical trials: Perspectives on some recent ideas. N Engl J Med 295: 74-80, 1976
31. Pocock SJ, Elbourne DR: Randomized trials or observational tribulations? N Engl J Med 342: 1907-1909, 2000
32. Suissa S: Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167: 492-499, 2008
33. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[Suppl 3]: S112-S119, 1998 (Pubitemid 28527268)
34. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 291: 451-459, 2004 (Pubitemid 38129749)
35. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994
36. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339: 1349-1357, 1998
37. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002
38. Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15: 458-482, 1990
39. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD: Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis 42: 864-881, 2003 (Pubitemid 37322905)
40. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
41. Forrester JS, Libby P: The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 99: 732-738, 2007 (Pubitemid 46273318)
42. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207, 2008
43. Pepys MB, Hirschfield GM: C-reactive protein: A critical update. J Clin Invest 111: 1805-1812, 2003
44. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227-239, 2004
45. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009, 1996
46. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622, 1998
47. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360: 7-22, 2002 (Pubitemid 34756487)
48. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355: 549-559, 2006
49. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, Schwartz JS: Rethinking randomized clinical trials for comparative effectiveness research: The need for transformational change. Ann Intern Med 151: 206-209, 2009